20. The compound or pharmaceutically acceptable salt of any one of claims 1 to 3, for use in a method as defined in claim 1, wherein:

n is 0;

C is furan;

b is 1; and

R^8 is halo, nitro, alkyl or cyano.

21. The compound or pharmaceutically acceptable salt of claim 20, for use in a method as defined in claim 1, wherein:

R^8 is alkyl.

22. The compound or pharmaceutically acceptable salt of claim 20, for use in a method as defined in claim 1, wherein:

R^8 is Cl, Br, nitro, methyl or cyano.

23. The compound or pharmaceutically acceptable salt of claim 22, for use in a method as defined in claim 1, wherein:

R^8 is methyl.

24. Use of a compound or pharmaceutically acceptable salt as defined in any one of claims 20 to 23 in the preparation of a medicament for modulating *in vivo* nitroxyl levels, treating a disease or condition that is responsive to nitroxyl therapy, treating a cardiovascular disease or condition, or treating heart failure.

25. Use of a compound or pharmaceutically acceptable salt as defined in any one of claims 20 to 23 in the preparation of a medicament for treating heart failure.

26. A compound or pharmaceutically acceptable salt as defined in any one of claims 20 to 23.

27. A pharmaceutical composition comprising a compound of any one of claims 20 to 23 or 26, and a pharmaceutically acceptable carrier.